Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?

E.A. Reijm, J.V. van Thienen, S. Wilgenhof, A. Bex, J.B.A.G. Haanen
2019 Kidney Cancer  
Treatment of renal cell carcinoma (RCC) has evolved rapidly since the development of checkpoint inhibitors. Most of the studies have been conducted in patients with metastatic disease and led to a significant change in the treatment landscape. Currently, many studies are investigating immune checkpoint inhibition (ICI) in the neoadjuvant and adjuvant setting and the efficacy of combination therapies. It remains difficult to predict which patients will respond best. Consequently, there is a high
more » ... need for predictive biomarkers. In this review, we discuss the different studies with ICI in RCC and the molecular correlates with clinical outcome.
doi:10.3233/kca-190065 fatcat:zvdpvq24yrcxnksfsdno3huvmu